Multidrug Regimen Could Change Treatment Landscape for Relapsed/Refractory DLBCL

Published Date: 21 Jun 2024

High-rate of durable responses with ViPOR sparks talk of supplanting CAR-T in second line

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

There has been a recent decrease in the risk of a recurrence of colorectal cancer in stage I to III cases.

2.

In NSCLC, subcutaneous Lazertinib + Amivantamab Dosing Is Not Worse Than IV Dosing.

3.

Recurrent UTIs impact eGFR in children with vesicoureteral reflux

4.

Month-Long Wait Times Caused by US Physician Shortage.

5.

Pharyngoesophageal junction cancer is not a good candidate for endoscopically assisted transoral surgery.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot